CompletedNCT00919139
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
Studying AL amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Joshua Espstein, DSCUniversity of Arkansas
- Intervention
- biologic sample preservation procedure(other)
- Enrollment
- 190 enrolled
- Eligibility
- All sexes
- Timeline
- 2003 – 2010
Study locations (30)
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States
- Peninsula Medical Center, Burlingame, California, United States
- University of California Davis Cancer Center, Sacramento, California, United States
- California Pacific Medical Center - California Campus, San Francisco, California, United States
- Sutter Health - Western Division Cancer Research Group, San Rafael, California, United States
- Sutter Solano Medical Center, Vallejo, California, United States
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
- M.D. Anderson Cancer Center at Orlando, Orlando, Florida, United States
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States
- Piedmont Hospital, Atlanta, Georgia, United States
- Northside Hospital Cancer Center, Atlanta, Georgia, United States
- Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States
- CCOP - Atlanta Regional, Atlanta, Georgia, United States
- WellStar Cobb Hospital, Austell, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00919139 on ClinicalTrials.govOther trials for AL amyloidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06963216A Study Investigating Coagadex in the Treatment AFXD Associated With AL AmyloidosisKedrion S.p.A.
- RECRUITINGPHASE3NCT07388602A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)Sinocelltech Ltd.
- RECRUITINGPHASE1, PHASE2NCT07266116Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis PatientsShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- RECRUITINGNCT07448935One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMSFondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGNCT07448779Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and TreatmentFondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGPHASE2NCT07110844Teclistamab-Daratumumab in AL AmyloidosisSuzanne Lentzsch, MD
- RECRUITINGPHASE1NCT07250269Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL AmyloidosisGracell Biotechnologies (Shanghai) Co., Ltd.
- RECRUITINGNCT07172243BE.Amycon Biobank & Data Registry UZ LeuvenUniversitaire Ziekenhuizen KU Leuven